• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ipsen to relocate headquarters to New Jersey

Ipsen to relocate headquarters to New Jersey

April 25, 2012
CenterWatch Staff

Ipsen, a global specialty-driven pharmaceutical company, has decided to open new commercial headquarters in Basking Ridge, N.J.

The move is an important step forward for Ipsen in the U.S., after the significant investment in its Mass.-based facility focused on R&D and technical operations (notably bioproduction) and the recently announced completion of its U.S. Leadership Team for commercial operations.

Relocation of the company’s headquarters is expected to create more than 100 new full-time jobs in New Jersey where the growing pharmaceutical and biopharmaceutical industries were key factors in Ipsen’s decision to establish U.S. headquarters in the state.

“For Ipsen, the U.S. is a new market in which we see significant opportunity. The move to New Jersey gives us access to the best talents of the biopharma industry, critical to Ipsen’s growth,” said Marc de Garidel, chairman and CEO of Ipsen.

Garidel added that the new headquarters “conveys our commitment to provide care to patient communities in the U.S., and will enable us to expand Ipsen’s capabilities and capacity in the U.S. marketplace for our specialty endocrine and neurology products.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing